Related Experiment Video
Updated: Jun 13, 2026
09:16
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1
Yasuhiko Kamikubo1, Ling Zhao, Mark Wunderlich
1Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cancer Cell
|May 19, 2010
Summary
Dominant RUNX1 inhibition is thought to drive CBF leukemia. However, this study shows that CBF beta-SMMHC lacking its binding domain accelerates leukemia, suggesting RUNX1 inhibition isn't critical for this cancer.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- RUNX1 (Runt-related transcription factor 1) is crucial for hematopoiesis.
- Dominant inhibition of RUNX1 is a proposed mechanism in Core Binding Factor (CBF) leukemia.
- CBF beta-SMMHC is an AML-associated fusion protein that inhibits RUNX1.
Purpose of the Study:
- To investigate the role of the RUNX1 high-affinity binding domain (HABD) in CBF beta-SMMHC-induced leukemogenesis.
- To determine if dominant RUNX1 inhibition is essential for leukemia development in the context of CBF beta-SMMHC.
Main Methods:
- Generated knockin mice expressing CBF beta-SMMHC lacking HABD.
- Assessed leukemia development and hematopoietic defects in these mice.
- Analyzed RUNX1 binding, MN1 expression, and RUNX1 phosphorylation.
Main Results:
- Mice expressing CBF beta-SMMHC without HABD developed leukemia rapidly.
- Hematopoietic defects linked to RUNX1 inhibition were partially rescued.
- Accelerated leukemia was associated with increased leukemia-initiating cells, elevated MN1 expression, and sustained RUNX1 phosphorylation.
Conclusions:
- The type I CBF beta-SMMHC fusion protein binds RUNX1 inefficiently.
- Dominant RUNX1 inhibition may not be a critical mechanism for leukemogenesis driven by CBF beta-SMMHC.
- Alternative pathways, including MN1 upregulation, contribute to leukemia development.
Related Concept Videos
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20Mismatch Repair
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
01:39Mutations
Overview
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...